4-叔丁基苯氧基乙基-N,N-二乙胺 | 57586-10-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-叔丁基苯氧基乙基-N,N-二乙胺
• 英文名称: diethyl-[2-(4-tert-butyl-phenoxy)-ethyl]-amine
• 英文别名: 2-Diaethylamino-1-(4-tert.-butyl-phenoxy)-aethan；Diaethyl-[2-(4-tert-butyl-phenoxy)-aethyl]-amin；2-(4-t-butylphenoxy)-triethylamine；4-tert-Butylphenoxyethyl-N,N-diethylamine；2-(4-tert-butylphenoxy)-N,N-diethylethanamine
• CAS: 57586-10-4
• 化学式: C₁₆H₂₇NO
• mdl: MFCD02030891
• 分子量: 249.396
• InChiKey: RSGRNBSLZBTWJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.625
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-叔丁基苯酚 、 2-二乙氨基氯乙烷盐酸盐 在 乙醇 、 sodium ethanolate 、 sodium iodide 作用下， 生成 4-叔丁基苯氧基乙基-N,N-二乙胺
  参考文献：
  名称：

  Burger et al., Journal of the American Chemical Society, 1945, vol. 67, p. 1416,1417

  摘要：

  DOI：

文献信息

• INHIBITORS OF THE BMP SIGNALING PATHWAY
  申请人：Yu Paul B.

  公开号：US20110053930A1

  公开（公告）日：2011-03-03

  The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.

  本发明提供了BMP信号通路的小分子抑制剂。这些化合物可以用于调节细胞生长、分化、增殖和凋亡，因此可能有用于治疗与BMP信号通路相关的疾病或病症，包括炎症、心血管疾病、血液疾病、癌症和骨骼疾病，以及调节细胞分化和/或增殖。
• MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
  申请人：PARK John Edward

  公开号：US20100204211A1

  公开（公告）日：2010-08-12

  The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R 1 to R 5 and X are defined as in claim 1 , the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.

  本发明涉及使用通式中6位取代的吲哚酮，其中R1至R5和X如权利要求1所定义，其异构体和盐，特别是其生理上可接受的盐，作为预防或治疗特定纤维化疾病的药物。
• Activation of the Renin-Angiotensin System (RAS) and Sudden Cardiac Death
  申请人：Dudley Samuel

  公开号：US20110207741A1

  公开（公告）日：2011-08-25

  Provided herein are methods of treating a medical condition in which RAS activation is increased. The method comprises the step of administering to a subject a c-Src inhibitor in an amount effective to treat the medical condition. The invention also provides a method of treating or preventing a cardiac arrhythmia. The method comprises the step of administering to the subject a c-Src inhibitor in an amount effective to treat or prevent the cardiac arrhythmia. The invention additionally provides a method of delaying the onset of sudden cardiac death. The method comprises the step of administering to the subject a c-Src inhibitor in an amount effective to delay the onset of SCD. Methods of augmenting gap junction function and methods of increasing Connexin 43 levels in a subject in need thereof are further provided.
• MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DEISEASES
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20190038600A1

  公开（公告）日：2019-02-07

  The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R 1 to R 5 and X are defined as in claim 1 , the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
• BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS
  申请人：G1 Therapeutics, Inc.

  公开号：US20210171554A1

  公开（公告）日：2021-06-10

  This invention is a benzothiophene estrogen receptor modulator or its pharmaceutically acceptable salt, N-oxide, isotopic derivative, or prodrug thereof or a pharmaceutically acceptable composition thereof to treat an estrogen-related medical disorder. The invention also includes a combination thereof with another active agent such as a CDK inhibitor, including a CDK4/6 inhibitor, to treat a disorder mediated by the estrogen receptor, as described in more detail herein.